Erectile Dysfunction
Conditions
Brief summary
A multicenter open label study to assess the efficacy of sildenafil rapid dose titration to 100 mg in men with erectile dysfunction, based on the Erectile Function (EF) domain score of the International Index of Erectile Function (IIEF) questionnaire.
Interventions
Tablets, 50mg and 100mg , Medication will be taken orally with a glass of water approximately one hour (30 min to 4 hours) before sexual activity. Subjects are to take one dose in any calendar day.Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil 100 mg PRN for the following four weeks.
Sponsors
Study design
Eligibility
Inclusion criteria
* Documented Clinical diagnosis of Erectile Dysfunction (ED) by International Index of Erectile Function (IIEF) Erectile Function (EF) Domain score less than or equal to 25. * Subjects must be in a stable relationship
Exclusion criteria
* Subject with resting sitting hypotension (BP \<90/50 mmHg) or hypertension (BP\>170/110 mmHg) and orthostatic hypotension. * Subjects receiving any PDE (Phosphodiesterase)-5 inhibitors within 4 weeks prior to the date of screening. * Subjects with severe hepatic impairment, a known history of retinitis pigmentare. * Subjects with significant cardiovascular disease in the last 3 months (per medical history.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| International Index of Erectile Function (IIEF), Erectile Function (EF) Domain Score- Change From Baseline to Week 6 Last Observation Carried Forward (LOCF) | Week 6 LOCF | IIEF is a self-administered scale designed to assess erectile functioning: includes 15 questions on 5 relevant domains of male sexual function; one is erectile function (EF). IIEF-EF Domain: sum of scores for Questions 1, 2, 3, 4, 5 & 15 from IIEF. Score range: 0 to 5 (Q1 to Q5), 1 to 5 (Q15); total 1 to 30. Higher score indicates better outcome. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| International Index of Erectile Function (IIEF), Erectile Function (EF) Domain Score- Change From Week 2 | Week 4 and Week 6 | IIEF is a self-administered scale designed to assess erectile functioning: includes 15 questions on 5 relevant domains of male sexual function; one is erectile function (EF). IIEF-EF Domain: sum of scores for Questions 1, 2, 3, 4, 5 & 15 from IIEF. Score range: 0 to 5 (Q1 to Q5), 1 to 5 (Q15); total 1 to 30. Higher score indicates better outcome. |
| International Index of Erectile Function (IIEF), Orgasmic Function Domain- Change From Baseline | Week 2, Week 4 and Week 6 | IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one is orgasmic function. IIEF Orgasmic Function Domain was sum of scores for Questions 9 and 10 from the IIEF. Score range: 0 to 5; total 0 to 10. Higher score indicates better outcome. |
| International Index of Erectile Function (IIEF), Orgasmic Function Domain- Change From Week 2 | Week 4 and Week 6 | IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one is orgasmic function. IIEF Orgasmic Function Domain was sum of scores for Questions 9 and 10 from the IIEF. Score range: 0 to 5; total 0 to 10. Higher score indicates better outcome. |
| International Index of Erectile Function (IIEF), Sexual Desire Domain Score- Change From Baseline | Week 2, Week 4 and Week 6 | IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one of which is sexual desire. IIEF Sexual Desire Domain was sum of scores for Questions 11 and 12 from the IIEF. Score range: 1 to 5; total 2 to 10. Higher score indicates better outcome. |
| International Index of Erectile Function (IIEF), Sexual Desire Domain Score- Change From Week 2 | Week 4 and Week 6 | IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one of which is sexual desire. IIEF Sexual Desire Domain was sum of scores for Questions 11 and 12 from the IIEF. Score range: 1 to 5; total 2 to 10. Higher score indicates better outcome. |
| International Index of Erectile Function (IIEF), Intercourse Satisfaction Domain Score- Change From Baseline | Week 2, Week 4, and Week 6 | IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one is intercourse satisfaction. IIEF Intercourse Satisfaction Domain: sum of scores for Questions 6, 7 and 8 from IIEF. Score range: 0 to 5; total 0 to 15. Higher score indicates better outcome. |
| International Index of Erectile Function (IIEF), Intercourse Satisfaction Domain Score- Change From Week 2 | Week 4 and Week 6 | IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one is intercourse satisfaction. IIEF Intercourse Satisfaction Domain: sum of scores for Questions 6, 7 and 8 from IIEF. Score range: 0 to 5; total 0 to 15. Higher score indicates better outcome. |
| International Index of Erectile Function (IIEF), Overall Satisfaction Domain Score- Change From Baseline | Week 2, Week 4 and Week 6 | IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one is overall satisfaction. IIEF Overall Satisfaction Domain was sum of scores for Questions 13 and 14 from the IIEF. Score range: 1 to 5; total 2 to 10. Higher score indicates better outcome. |
| International Index of Erectile Function (IIEF), Overall Satisfaction Domain Score- Change From Week 2 | Week 4 and Week 6 | IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one is overall satisfaction. IIEF Overall Satisfaction Domain was sum of scores for Questions 13 and 14 from the IIEF. Score range: 1 to 5; total 2 to 10. Higher score indicates better outcome. |
| Quality of Erection Questionnaire (QEQ): Total Score - Change From Baseline | Week 2, Week 4, and Week 6 | QEQ is a self-administered scale used to assess erection hardness and overall quality of erections. The QEQ total score is defined as the sum of the scores from QEQ Questions 1-6. Score range: 1 to 5. Higher score indicates better outcome. Raw QEQ score ranges from 6-30 and is transformed onto a 0-100 scale. |
| Quality of Erection Questionnaire (QEQ): Total Score- Change From Week 2 | Week 4 and Week 6 | QEQ is a self-administered scale used to assess erection hardness and overall quality of erections. The QEQ total score is defined as the sum of the scores from QEQ Questions 1-6. Score range: 1 to 5. Higher score indicates better outcome. Raw QEQ score ranges from 6-30 and is transformed onto a 0-100 scale. |
| Sexual Experience Questionnaire (Sex-Q): Erection Domain - Change From Baseline | Week 2, Week 4 and Week 6 | Sexual Experience Questionnaire (Sex-Q) is a self-administered questionnaire designed to assess functional, emotional, and social aspects of sexual experience. Sex-Q includes 15 questions. Sex-Q Erection domain: sum of scores for Questions 1, 2, 3, 4, 5 and 6 from the Sex-Q. Score range: 1 to 5; total 6 to 30. Higher score indicates better outcome. |
| Sexual Experience Questionnaire (Sex-Q): Erection Domain- Change From Week 2 | Week 4 and Week 6 | Sexual Experience Questionnaire (Sex-Q) is a self-administered questionnaire designed to assess functional, emotional, and social aspects of sexual experience. Sex-Q includes 15 questions. Sex-Q Erection domain: sum of scores for Questions 1, 2, 3, 4, 5 and 6 from the Sex-Q. Score range: 1 to 5; total 6 to 30. Higher score indicates better outcome. |
| Sexual Experience Questionnaire (Sex-Q): Satisfaction Domain - Change From Baseline | Week 2, Week 4, and Week 6 | Sexual Experience Questionnaire (Sex-Q) is a self-administered questionnaire designed to assess functional, emotional, and social aspects of sexual experience. Sex-Q includes 15 questions (q). Sex-Q Satisfaction domain:sum of scores for q 10, 11, 12, 13, 14 and 15 from Sex-Q. Score range:1 to 5; total 6 to 30. Higher score indicates better outcome |
| Sexual Experience Questionnaire (Sex-Q): Satisfaction Domain - Change From Week 2 | Week 4 and Week 6 | Sexual Experience Questionnaire (Sex-Q) is a self-administered questionnaire designed to assess functional, emotional, and social aspects of sexual experience. Sex-Q includes 15 questions (q). Sex-Q Satisfaction domain:sum of scores for q 10, 11, 12, 13, 14 and 15 from Sex-Q. Score range:1 to 5; total 6 to 30. Higher score indicates better outcome |
| Sexual Experience Questionnaire (Sex-Q): Relationship Domain - Change From Baseline | Week 2, Week 4, and Week 6 | Sexual Experience Questionnaire (Sex-Q) is a self-administered questionnaire designed to assess functional, emotional, and social aspects of sexual experience. Sex-Q includes 15 questions. Sex-Q Relationship domain was sum of scores for Questions 7, 8 and 9 from the Sex-Q. Score range: 1 to 5; total 3 to 15. Higher score indicates better outcome. |
| Sexual Experience Questionnaire (Sex-Q): Relationship Domain - Change From Week 2 | Week 4 and Week 6 | Sexual Experience Questionnaire (Sex-Q) is a self-administered questionnaire designed to assess functional, emotional, and social aspects of sexual experience. Sex-Q includes 15 questions. Sex-Q Relationship domain was sum of scores for Questions 7, 8 and 9 from the Sex-Q. Score range: 1 to 5; total 3 to 15. Higher score indicates better outcome. |
| Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 1 on Occasions With Sexual Stimulation- Change From Baseline | Week 2, Week 4 and Week 6 | Mean change: mean change at each visit minus mean at baseline. Percent of Yes responses to Question 1 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 1 \[Were you able to achieve at least some erection (some enlargement of the penis)?\] = Yes) / (number of occasions where Question 1 was answered Yes or No) |
| Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 1 Based on Occasions With Sexual Stimulation- Change From Week 2 | Week 4 and Week 6 | Mean change: mean change at each visit minus mean at Week 2. Percent of Yes responses to Question 1 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 1 \[Were you able to achieve at least some erection (some enlargement of the penis)?\] = Yes) / (number of occasions where Question 1 was answered Yes or No) |
| Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 2 on Occasions With Sexual Stimulation- Change From Baseline | Week 2, Week 4 and Week 6 | Mean change: mean change at each visit minus mean at baseline. Percent of Yes responses to SEP Question 2 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 2 \[Were you able to insert your penis into your partner's vagina?\] = Yes) / (number of occasions where SEP Question 2 was answered Yes or No). |
| Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 2 on Occasions With Sexual Stimulation- Change From Week 2 | Week 4 and Week 6 | Mean change: mean change at each visit minus mean at Week 2. Percent of Yes responses to SEP Question 2 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 2 \[Were you able to insert your penis into your partner's vagina?\] = Yes) / (number of occasions where SEP Question 2 was answered Yes or No). |
| Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 on Occasions With Sexual Stimulation- Change From Baseline | Week 2, Week 4 and Week 6 | Mean change: mean change at each visit minus mean at baseline. Percent of Yes responses to SEP Question 2 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 3 \[Did your erection last long enough for you to have successful intercourse?\] = Yes) / (number of occasions where SEP Question 3 was answered Yes or No) |
| Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 Based on Occasions With Sexual Stimulation- Change From Week 2 | Week 4 and Week 6 | Mean change: mean change at each visit minus mean at Week 2. Percent of Yes responses to SEP Question 2 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 3 \[Did your erection last long enough for you to have successful intercourse?\] = Yes) / (number of occasions where SEP Question 3 was answered Yes or No) |
| Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 4 Based on Occasions With Sexual Stimulation- Change From Baseline | Week 2, Week 4 and Week 6 | Mean change: mean change at each visit minus mean at baseline. Percent of Yes responses to SEP Question 4 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 4 \[Were you satisfied with the hardness of your erection?\] = Yes) / (number of occasions where SEP Question 4 was answered Yes or No). |
| Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 4 Based on Occasions With Sexual Stimulation- Change From Week 2 | Week 4 and Week 6 | Mean change: mean change at each visit minus mean at Week 2. Percent of Yes responses to SEP Question 4 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 4 \[Were you satisfied with the hardness of your erection?\] = Yes) / (number of occasions where SEP Question 4 was answered Yes or No). |
| Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 5 Based on Occasions With Sexual Stimulation- Change From Baseline | Week 2, Week 4 and Week 6 | Mean change: mean change at each visit minus mean at baseline. Percent of Yes responses to SEP Question 5 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 5 \[Were you satisfied with this sexual encounter?\] = Yes) / (number of occasions where SEP Question 5 was answered Yes or No) |
| Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 5 Based on Occasions With Sexual Stimulation- Change From Week 2 | Week 4 and Week 6 | Mean change: mean change at each visit minus mean at Week 2. Percent of Yes responses to SEP Question 5 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 5 \[Were you satisfied with this sexual encounter?\] = Yes) / (number of occasions where SEP Question 5 was answered Yes or No) |
| Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 (Q3) Based on Attempts With Sexual Stimulation- Change From Baseline | Week 2, Week 4, and Week 6 | Mean change: mean change at each visit minus mean at baseline. Percent of Yes responses to SEP Q3 based on attempts with sexual stimulation (SS): 100\* (number of attempts with SS where SEP Q3 \[Did your erection last long enough for you to have successful intercourse?\] = Yes)/(number of attempts with SS where SEP Q3 was answered Yes or No) |
| Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 (Q3) Based on Attempts With Sexual Stimulation- Change From Week 2 | Week 4 and Week 6 | Mean change: mean change at each visit minus mean at Week 2. Percent of Yes responses to SEP Q3 based on attempts with sexual stimulation (SS): 100\* (number of attempts with SS where SEP Q3 \[Did your erection last long enough for you to have successful intercourse?\] = Yes)/(number of attempts with SS where SEP Q3 was answered Yes or No) |
| Mean Per-Patient Percentage of Grade 1 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation- Change From Baseline | Week 2, Week 4 and Week 6 | Mean change: mean change at each visit minus mean at baseline. Percent of Grade 1 (1=increase in size, but not hard) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 1)/(number of occasions where Erection Hardness Scale was answered) |
| Mean Per-Patient Percentage of Grade 1 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation- Change From Week 2 | Week 4 and Week 6 | Mean change: mean change at each visit minus mean at Week 2. Percent of Grade 1 (1=increase in size, but not hard) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 1)/(number of occasions where Erection Hardness Scale was answered) |
| Mean Per-Patient Percentage of Grade 2 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Baseline | Week 2, Week 4 and Week 6 | Mean change: mean change at each visit minus mean at baseline. Percent of Grade 2 (2= hard, but not hard enough for penetration) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 2)/(number of occasions where Erection Hardness Scale was answered) |
| Mean Per-Patient Percentage of Grade 2 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2 | Week 4 and Week 6 | Mean change: mean change at each visit minus mean at Week 2. Percent of Grade 2 (2= hard, but not hard enough for penetration) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 2)/(number of occasions where Erection Hardness Scale was answered) |
| Mean Per-Patient Percentage of Grade 3 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Baseline | Week 2, Week 4 and Week 6 | Mean change: mean change at each visit minus mean at baseline. Percent of Grade 3 (3= hard enough for penetration \[but not completely hard\]) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 3)/(number of occasions where Erection Hardness Scale was answered) |
| International Index of Erectile Function (IIEF), Erectile Function (EF) Domain Score - Change From Baseline at Weeks 2, 4 and 6 | Week 2, Week 4 and Week 6 | IIEF is a self-administered scale designed to assess erectile functioning: includes 15 questions on 5 relevant domains of male sexual function; one is erectile function (EF). IIEF-EF Domain: sum of scores for Questions 1, 2, 3, 4, 5 & 15 from IIEF. Score range: 0 to 5 (Q1 to Q5), 1 to 5 (Q15); total 1 to 30. Higher score indicates better outcome. |
| Mean Per-Patient Percentage of Grade 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Baseline | Week 2, Week 4 and Week 6 | Mean change: mean change at each visit minus mean at baseline. Percent of Grade 4 (4= completely hard) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 4)/(number of occasions where Erection Hardness Scale was answered) |
| Mean Per-Patient Percentage of Grade 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2 | Week 4 and Week 6 | Mean change: mean change at each visit minus mean at Week 2. Percent of Grade 4 (4= completely hard) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 4)/(number of occasions where Erection Hardness Scale was answered) |
| Mean Per-Patient Percentage of Grade 3 or 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Baseline | Week 2, Week 4 and Week 6 | Mean change: mean change at each visit minus mean at baseline. Percent of Grade 3 (hard enough for penetration \[but not completely hard\]) or 4 (completely hard) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 3 or 4)/ (number of occasions where Erection Hardness Scale was answered) |
| Mean Per-Patient Percentage of Grade 3 or 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2 | Week 4 and Week 6 | Mean change: mean change at each visit minus mean at Week 2. Percent of Grade 3 (hard enough for penetration \[but not completely hard\]) or 4 (completely hard) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 3 or 4)/ (number of occasions where Erection Hardness Scale was answered) |
| Mean Per-Patient Percentage of Grade 3 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2 | Week 4 and Week 6 | Mean change: mean change at each visit minus mean at Week 2. Percent of Grade 3 (3= hard enough for penetration \[but not completely hard\]) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 3)/(number of occasions where Erection Hardness Scale was answered) |
Countries
Mexico
Participant flow
Pre-assignment details
Eligible subjects had to have at least 2 attempts at sexual intercourse during the 2 week screening phase to begin the sildenafil citrate 50mg treatment at baseline.
Participants by arm
| Arm | Count |
|---|---|
| Open Label Sildenafil Citrate Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil citrate 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil citrate 100 mg PRN for the following four weeks. | 117 |
| Total | 117 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Lost to Follow-up | 4 |
| Overall Study | Protocol Violation | 1 |
| Overall Study | Withdrawal by Subject | 2 |
Baseline characteristics
| Characteristic | Open Label Sildenafil Citrate |
|---|---|
| Age, Continuous | 53.3 years STANDARD_DEVIATION 11 |
| Sex: Female, Male Female | 0 Participants |
| Sex: Female, Male Male | 117 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 33 / — |
| serious Total, serious adverse events | 0 / 117 |
Outcome results
International Index of Erectile Function (IIEF), Erectile Function (EF) Domain Score- Change From Baseline to Week 6 Last Observation Carried Forward (LOCF)
IIEF is a self-administered scale designed to assess erectile functioning: includes 15 questions on 5 relevant domains of male sexual function; one is erectile function (EF). IIEF-EF Domain: sum of scores for Questions 1, 2, 3, 4, 5 & 15 from IIEF. Score range: 0 to 5 (Q1 to Q5), 1 to 5 (Q15); total 1 to 30. Higher score indicates better outcome.
Time frame: Week 6 LOCF
Population: Modified intent to treat (MITT) population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, last assessment collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Open Label Sildenafil Citrate | International Index of Erectile Function (IIEF), Erectile Function (EF) Domain Score- Change From Baseline to Week 6 Last Observation Carried Forward (LOCF) | 10.96 score on scale | Standard Deviation 5.19 |
International Index of Erectile Function (IIEF), Erectile Function (EF) Domain Score - Change From Baseline at Weeks 2, 4 and 6
IIEF is a self-administered scale designed to assess erectile functioning: includes 15 questions on 5 relevant domains of male sexual function; one is erectile function (EF). IIEF-EF Domain: sum of scores for Questions 1, 2, 3, 4, 5 & 15 from IIEF. Score range: 0 to 5 (Q1 to Q5), 1 to 5 (Q15); total 1 to 30. Higher score indicates better outcome.
Time frame: Week 2, Week 4 and Week 6
Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. Week 6 Endpoint = last observation recorded after Week 2
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Open Label Sildenafil Citrate | International Index of Erectile Function (IIEF), Erectile Function (EF) Domain Score - Change From Baseline at Weeks 2, 4 and 6 | Week 2 (N=113) | 7.14 score on a scale | Standard Deviation 5.21 |
| Open Label Sildenafil Citrate | International Index of Erectile Function (IIEF), Erectile Function (EF) Domain Score - Change From Baseline at Weeks 2, 4 and 6 | Week 4 (N=112) | 10.57 score on a scale | Standard Deviation 5.43 |
| Open Label Sildenafil Citrate | International Index of Erectile Function (IIEF), Erectile Function (EF) Domain Score - Change From Baseline at Weeks 2, 4 and 6 | Week 6 (N=110) | 10.93 score on a scale | Standard Deviation 5.26 |
| Open Label Sildenafil Citrate | International Index of Erectile Function (IIEF), Erectile Function (EF) Domain Score - Change From Baseline at Weeks 2, 4 and 6 | Week 6 Endpoint (N=112) | 10.95 score on a scale | Standard Deviation 5.21 |
International Index of Erectile Function (IIEF), Erectile Function (EF) Domain Score- Change From Week 2
IIEF is a self-administered scale designed to assess erectile functioning: includes 15 questions on 5 relevant domains of male sexual function; one is erectile function (EF). IIEF-EF Domain: sum of scores for Questions 1, 2, 3, 4, 5 & 15 from IIEF. Score range: 0 to 5 (Q1 to Q5), 1 to 5 (Q15); total 1 to 30. Higher score indicates better outcome.
Time frame: Week 4 and Week 6
Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Open Label Sildenafil Citrate | International Index of Erectile Function (IIEF), Erectile Function (EF) Domain Score- Change From Week 2 | Week 4 (N=112) | 3.48 score on scale | Standard Deviation 3.97 |
| Open Label Sildenafil Citrate | International Index of Erectile Function (IIEF), Erectile Function (EF) Domain Score- Change From Week 2 | Week 6 (N=110) | 3.88 score on scale | Standard Deviation 4.38 |
| Open Label Sildenafil Citrate | International Index of Erectile Function (IIEF), Erectile Function (EF) Domain Score- Change From Week 2 | Week 6 LOCF (N=112) | 3.86 score on scale | Standard Deviation 4.35 |
| Open Label Sildenafil Citrate | International Index of Erectile Function (IIEF), Erectile Function (EF) Domain Score- Change From Week 2 | Week 6 Endpoint (N=112) | 3.86 score on scale | Standard Deviation 4.35 |
International Index of Erectile Function (IIEF), Intercourse Satisfaction Domain Score- Change From Baseline
IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one is intercourse satisfaction. IIEF Intercourse Satisfaction Domain: sum of scores for Questions 6, 7 and 8 from IIEF. Score range: 0 to 5; total 0 to 15. Higher score indicates better outcome.
Time frame: Week 2, Week 4, and Week 6
Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Open Label Sildenafil Citrate | International Index of Erectile Function (IIEF), Intercourse Satisfaction Domain Score- Change From Baseline | Week 2 (N=113) | 3.18 score on scale | Standard Deviation 2.42 |
| Open Label Sildenafil Citrate | International Index of Erectile Function (IIEF), Intercourse Satisfaction Domain Score- Change From Baseline | Week 4 (N=112) | 4.38 score on scale | Standard Deviation 2.39 |
| Open Label Sildenafil Citrate | International Index of Erectile Function (IIEF), Intercourse Satisfaction Domain Score- Change From Baseline | Week 6 (N=110) | 4.73 score on scale | Standard Deviation 2.53 |
| Open Label Sildenafil Citrate | International Index of Erectile Function (IIEF), Intercourse Satisfaction Domain Score- Change From Baseline | Week 6 LOCF (N=113) | 4.70 score on scale | Standard Deviation 2.52 |
| Open Label Sildenafil Citrate | International Index of Erectile Function (IIEF), Intercourse Satisfaction Domain Score- Change From Baseline | Week 6 Endpoint (N=112) | 4.72 score on scale | Standard Deviation 2.52 |
International Index of Erectile Function (IIEF), Intercourse Satisfaction Domain Score- Change From Week 2
IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one is intercourse satisfaction. IIEF Intercourse Satisfaction Domain: sum of scores for Questions 6, 7 and 8 from IIEF. Score range: 0 to 5; total 0 to 15. Higher score indicates better outcome.
Time frame: Week 4 and Week 6
Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Open Label Sildenafil Citrate | International Index of Erectile Function (IIEF), Intercourse Satisfaction Domain Score- Change From Week 2 | Week 4 (N=112) | 1.20 score on scale | Standard Deviation 2.1 |
| Open Label Sildenafil Citrate | International Index of Erectile Function (IIEF), Intercourse Satisfaction Domain Score- Change From Week 2 | Week 6 (N=110) | 1.54 score on scale | Standard Deviation 2.2 |
| Open Label Sildenafil Citrate | International Index of Erectile Function (IIEF), Intercourse Satisfaction Domain Score- Change From Week 2 | Week 6 LOCF (N=112) | 1.54 score on scale | Standard Deviation 2.19 |
| Open Label Sildenafil Citrate | International Index of Erectile Function (IIEF), Intercourse Satisfaction Domain Score- Change From Week 2 | Week 6 Endpoint (N=112) | 1.54 score on scale | Standard Deviation 2.19 |
International Index of Erectile Function (IIEF), Orgasmic Function Domain- Change From Baseline
IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one is orgasmic function. IIEF Orgasmic Function Domain was sum of scores for Questions 9 and 10 from the IIEF. Score range: 0 to 5; total 0 to 10. Higher score indicates better outcome.
Time frame: Week 2, Week 4 and Week 6
Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Open Label Sildenafil Citrate | International Index of Erectile Function (IIEF), Orgasmic Function Domain- Change From Baseline | Week 2 (N=113) | 1.89 score on scale | Standard Deviation 2.4 |
| Open Label Sildenafil Citrate | International Index of Erectile Function (IIEF), Orgasmic Function Domain- Change From Baseline | Week 4 (N=112) | 2.46 score on scale | Standard Deviation 2.32 |
| Open Label Sildenafil Citrate | International Index of Erectile Function (IIEF), Orgasmic Function Domain- Change From Baseline | Week 6 (N=110) | 2.59 score on scale | Standard Deviation 2.44 |
| Open Label Sildenafil Citrate | International Index of Erectile Function (IIEF), Orgasmic Function Domain- Change From Baseline | Week 6 LOCF (N=113) | 2.63 score on scale | Standard Deviation 2.45 |
| Open Label Sildenafil Citrate | International Index of Erectile Function (IIEF), Orgasmic Function Domain- Change From Baseline | Week 6 Endpoint (N=112) | 2.59 score on scale | Standard Deviation 2.42 |
International Index of Erectile Function (IIEF), Orgasmic Function Domain- Change From Week 2
IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one is orgasmic function. IIEF Orgasmic Function Domain was sum of scores for Questions 9 and 10 from the IIEF. Score range: 0 to 5; total 0 to 10. Higher score indicates better outcome.
Time frame: Week 4 and Week 6
Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Open Label Sildenafil Citrate | International Index of Erectile Function (IIEF), Orgasmic Function Domain- Change From Week 2 | Week 4 (N=112) | 0.61 score on scale | Standard Deviation 1.51 |
| Open Label Sildenafil Citrate | International Index of Erectile Function (IIEF), Orgasmic Function Domain- Change From Week 2 | Week 6 (N=110) | 0.75 score on scale | Standard Deviation 1.46 |
| Open Label Sildenafil Citrate | International Index of Erectile Function (IIEF), Orgasmic Function Domain- Change From Week 2 | Week 6 LOCF (N=112) | 0.74 score on scale | Standard Deviation 1.45 |
| Open Label Sildenafil Citrate | International Index of Erectile Function (IIEF), Orgasmic Function Domain- Change From Week 2 | Week 6 Endpoint (N=112) | 0.74 score on scale | Standard Deviation 1.45 |
International Index of Erectile Function (IIEF), Overall Satisfaction Domain Score- Change From Baseline
IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one is overall satisfaction. IIEF Overall Satisfaction Domain was sum of scores for Questions 13 and 14 from the IIEF. Score range: 1 to 5; total 2 to 10. Higher score indicates better outcome.
Time frame: Week 2, Week 4 and Week 6
Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Open Label Sildenafil Citrate | International Index of Erectile Function (IIEF), Overall Satisfaction Domain Score- Change From Baseline | Week 2 (N=113) | 2.73 score on scale | Standard Deviation 2.38 |
| Open Label Sildenafil Citrate | International Index of Erectile Function (IIEF), Overall Satisfaction Domain Score- Change From Baseline | Week 4 (N=112) | 3.67 score on scale | Standard Deviation 2.49 |
| Open Label Sildenafil Citrate | International Index of Erectile Function (IIEF), Overall Satisfaction Domain Score- Change From Baseline | Week 6 (N=110) | 3.92 score on scale | Standard Deviation 2.52 |
| Open Label Sildenafil Citrate | International Index of Erectile Function (IIEF), Overall Satisfaction Domain Score- Change From Baseline | Week 6 LOCF (N=113) | 3.91 score on scale | Standard Deviation 2.53 |
| Open Label Sildenafil Citrate | International Index of Erectile Function (IIEF), Overall Satisfaction Domain Score- Change From Baseline | Week 6 Endpoint (N=112) | 3.89 score on scale | Standard Deviation 2.53 |
International Index of Erectile Function (IIEF), Overall Satisfaction Domain Score- Change From Week 2
IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one is overall satisfaction. IIEF Overall Satisfaction Domain was sum of scores for Questions 13 and 14 from the IIEF. Score range: 1 to 5; total 2 to 10. Higher score indicates better outcome.
Time frame: Week 4 and Week 6
Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Open Label Sildenafil Citrate | International Index of Erectile Function (IIEF), Overall Satisfaction Domain Score- Change From Week 2 | Week 4 (N=112) | 0.97 score on scale | Standard Deviation 1.88 |
| Open Label Sildenafil Citrate | International Index of Erectile Function (IIEF), Overall Satisfaction Domain Score- Change From Week 2 | Week 6 (N=110) | 1.21 score on scale | Standard Deviation 1.92 |
| Open Label Sildenafil Citrate | International Index of Erectile Function (IIEF), Overall Satisfaction Domain Score- Change From Week 2 | Week 6 LOCF (N=112) | 1.20 score on scale | Standard Deviation 1.9 |
| Open Label Sildenafil Citrate | International Index of Erectile Function (IIEF), Overall Satisfaction Domain Score- Change From Week 2 | Week 6 Endpoint (N=112) | 1.20 score on scale | Standard Deviation 1.9 |
International Index of Erectile Function (IIEF), Sexual Desire Domain Score- Change From Baseline
IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one of which is sexual desire. IIEF Sexual Desire Domain was sum of scores for Questions 11 and 12 from the IIEF. Score range: 1 to 5; total 2 to 10. Higher score indicates better outcome.
Time frame: Week 2, Week 4 and Week 6
Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Open Label Sildenafil Citrate | International Index of Erectile Function (IIEF), Sexual Desire Domain Score- Change From Baseline | Week 2 (N=113) | 1.43 score on scale | Standard Deviation 1.87 |
| Open Label Sildenafil Citrate | International Index of Erectile Function (IIEF), Sexual Desire Domain Score- Change From Baseline | Week 4 (N=112) | 2.00 score on scale | Standard Deviation 1.86 |
| Open Label Sildenafil Citrate | International Index of Erectile Function (IIEF), Sexual Desire Domain Score- Change From Baseline | Week 6 (N=110) | 2.25 score on scale | Standard Deviation 1.91 |
| Open Label Sildenafil Citrate | International Index of Erectile Function (IIEF), Sexual Desire Domain Score- Change From Baseline | Week 6 LOCF (N=113) | 2.26 score on scale | Standard Deviation 1.94 |
| Open Label Sildenafil Citrate | International Index of Erectile Function (IIEF), Sexual Desire Domain Score- Change From Baseline | Week 6 Endpoint (N=112) | 2.28 score on scale | Standard Deviation 1.93 |
International Index of Erectile Function (IIEF), Sexual Desire Domain Score- Change From Week 2
IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one of which is sexual desire. IIEF Sexual Desire Domain was sum of scores for Questions 11 and 12 from the IIEF. Score range: 1 to 5; total 2 to 10. Higher score indicates better outcome.
Time frame: Week 4 and Week 6
Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Open Label Sildenafil Citrate | International Index of Erectile Function (IIEF), Sexual Desire Domain Score- Change From Week 2 | Week 4 (N=112) | 0.55 score on scale | Standard Deviation 1.41 |
| Open Label Sildenafil Citrate | International Index of Erectile Function (IIEF), Sexual Desire Domain Score- Change From Week 2 | Week 6 (N=110) | 0.81 score on scale | Standard Deviation 1.47 |
| Open Label Sildenafil Citrate | International Index of Erectile Function (IIEF), Sexual Desire Domain Score- Change From Week 2 | Week 6 LOCF (N=112) | 0.83 score on scale | Standard Deviation 1.49 |
| Open Label Sildenafil Citrate | International Index of Erectile Function (IIEF), Sexual Desire Domain Score- Change From Week 2 | Week 6 Endpoint (N=112) | 0.83 score on scale | Standard Deviation 1.49 |
Mean Per-Patient Percentage of Grade 1 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation- Change From Baseline
Mean change: mean change at each visit minus mean at baseline. Percent of Grade 1 (1=increase in size, but not hard) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 1)/(number of occasions where Erection Hardness Scale was answered)
Time frame: Week 2, Week 4 and Week 6
Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of Grade 1 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation- Change From Baseline | Grade 1 (Week 2) N=103 | -12.58 per-patient percentage | Standard Deviation 37.77 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of Grade 1 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation- Change From Baseline | Grade 1 (Week 4) N=101 | -20.55 per-patient percentage | Standard Deviation 35.04 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of Grade 1 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation- Change From Baseline | Grade 1 (Week 6) N=98 | -22.53 per-patient percentage | Standard Deviation 36.64 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of Grade 1 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation- Change From Baseline | Grade 1 (Week 6 LOCF) N=103 | -21.44 per-patient percentage | Standard Deviation 36.06 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of Grade 1 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation- Change From Baseline | Grade 1 (Week 6 Endpoint) N=101 | -21.86 per-patient percentage | Standard Deviation 36.29 |
Mean Per-Patient Percentage of Grade 1 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation- Change From Week 2
Mean change: mean change at each visit minus mean at Week 2. Percent of Grade 1 (1=increase in size, but not hard) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 1)/(number of occasions where Erection Hardness Scale was answered)
Time frame: Week 4 and Week 6
Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of Grade 1 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation- Change From Week 2 | Grade 1 (Week 4) N=110 | -6.79 per-patient percentage | Standard Deviation 22.58 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of Grade 1 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation- Change From Week 2 | Grade 1 (Week 6) N=107 | -6.85 per-patient percentage | Standard Deviation 23.02 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of Grade 1 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation- Change From Week 2 | Grade 1 (Week 6 LOCF) N=112 | -7.43 per-patient percentage | Standard Deviation 24.2 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of Grade 1 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation- Change From Week 2 | Grade 1 (Week 6 Endpoint) N=110 | -7.57 per-patient percentage | Standard Deviation 24.4 |
Mean Per-Patient Percentage of Grade 2 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Baseline
Mean change: mean change at each visit minus mean at baseline. Percent of Grade 2 (2= hard, but not hard enough for penetration) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 2)/(number of occasions where Erection Hardness Scale was answered)
Time frame: Week 2, Week 4 and Week 6
Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of Grade 2 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Baseline | Grade 2 (Week 2) N=103 | -9.87 Per-patient percentage | Standard Deviation 34.44 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of Grade 2 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Baseline | Grade 2 (Week 4) N=101 | -11.74 Per-patient percentage | Standard Deviation 32.8 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of Grade 2 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Baseline | Grade 2 (Week 6) N=98 | -12.78 Per-patient percentage | Standard Deviation 33.56 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of Grade 2 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Baseline | Grade 2 (Week 6 LOCF) N=103 | -13.13 Per-patient percentage | Standard Deviation 33.94 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of Grade 2 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Baseline | Grade 2 (Week 6 Endpoint) N=101 | -12.40 Per-patient percentage | Standard Deviation 33.13 |
Mean Per-Patient Percentage of Grade 2 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2
Mean change: mean change at each visit minus mean at Week 2. Percent of Grade 2 (2= hard, but not hard enough for penetration) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 2)/(number of occasions where Erection Hardness Scale was answered)
Time frame: Week 4 and Week 6
Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of Grade 2 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2 | Grade 2 (Week 4) N=110 | -2.39 per-patient percentage | Standard Deviation 22 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of Grade 2 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2 | Grade 2 (Week 6) N=107 | -1.91 per-patient percentage | Standard Deviation 20.73 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of Grade 2 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2 | Grade 2 (Week 6 LOCF) N=112 | -2.71 per-patient percentage | Standard Deviation 22.28 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of Grade 2 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2 | Grade 2 (Week 6 Endpoint) N=110 | -2.76 per-patient percentage | Standard Deviation 22.48 |
Mean Per-Patient Percentage of Grade 3 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Baseline
Mean change: mean change at each visit minus mean at baseline. Percent of Grade 3 (3= hard enough for penetration \[but not completely hard\]) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 3)/(number of occasions where Erection Hardness Scale was answered)
Time frame: Week 2, Week 4 and Week 6
Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of Grade 3 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Baseline | Grade 3 (Week 2) N=103 | -10.82 per-patient percentage | Standard Deviation 56.75 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of Grade 3 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Baseline | Grade 3 (Week 4) N=101 | -29.16 per-patient percentage | Standard Deviation 59.81 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of Grade 3 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Baseline | Grade 3 (Week 6) N=98 | -30.79 per-patient percentage | Standard Deviation 60.9 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of Grade 3 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Baseline | Grade 3 (Week 6 LOCF) N=103 | -30.27 per-patient percentage | Standard Deviation 61.7 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of Grade 3 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Baseline | Grade 3 (Week 6 Endpoint) N=101 | -30.87 per-patient percentage | Standard Deviation 60.54 |
Mean Per-Patient Percentage of Grade 3 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2
Mean change: mean change at each visit minus mean at Week 2. Percent of Grade 3 (3= hard enough for penetration \[but not completely hard\]) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 3)/(number of occasions where Erection Hardness Scale was answered)
Time frame: Week 4 and Week 6
Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of Grade 3 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2 | Grade 1 (Week 4) N=110 | -18.36 per-patient percentage | Standard Deviation 46.03 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of Grade 3 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2 | Grade 1 (Week 6) N=107 | -22.16 per-patient percentage | Standard Deviation 45.24 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of Grade 3 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2 | Grade 1 (Week 6 LOCF) N=112 | -20.28 per-patient percentage | Standard Deviation 45.86 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of Grade 3 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2 | Grade 1 (Week 6 Endpoint) N=110 | -20.65 per-patient percentage | Standard Deviation 46.2 |
Mean Per-Patient Percentage of Grade 3 or 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Baseline
Mean change: mean change at each visit minus mean at baseline. Percent of Grade 3 (hard enough for penetration \[but not completely hard\]) or 4 (completely hard) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 3 or 4)/ (number of occasions where Erection Hardness Scale was answered)
Time frame: Week 2, Week 4 and Week 6
Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of Grade 3 or 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Baseline | Grade 3 or 4 (Week 2) N=103 | 22.45 per-patient percentage | Standard Deviation 46.1 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of Grade 3 or 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Baseline | Grade 3 or 4 (Week 4) N=101 | 32.30 per-patient percentage | Standard Deviation 42.15 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of Grade 3 or 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Baseline | Grade 3 or 4 (Week 6) N=98 | 35.31 per-patient percentage | Standard Deviation 43.52 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of Grade 3 or 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Baseline | Grade 3 or 4 (Week 6 LOCF) N=103 | 34.57 per-patient percentage | Standard Deviation 43.48 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of Grade 3 or 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Baseline | Grade 3 or 4 (Week 6 Endpoint) N=101 | 34.26 per-patient percentage | Standard Deviation 43.29 |
Mean Per-Patient Percentage of Grade 3 or 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2
Mean change: mean change at each visit minus mean at Week 2. Percent of Grade 3 (hard enough for penetration \[but not completely hard\]) or 4 (completely hard) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 3 or 4)/ (number of occasions where Erection Hardness Scale was answered)
Time frame: Week 4 and Week 6
Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of Grade 3 or 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2 | Grade 3 or 4 (Week 4) N=110 | 9.18 per-patient percentage | Standard Deviation 29.45 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of Grade 3 or 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2 | Grade 3 or 4 (Week 6) N=107 | 8.75 per-patient percentage | Standard Deviation 29.26 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of Grade 3 or 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2 | Grade 3 or 4 (Week 6 LOCF ) N=112 | 10.15 per-patient percentage | Standard Deviation 31.11 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of Grade 3 or 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2 | Grade 3 or 4 (Week 6 Endpoint ) N=110 | 10.33 per-patient percentage | Standard Deviation 31.36 |
Mean Per-Patient Percentage of Grade 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Baseline
Mean change: mean change at each visit minus mean at baseline. Percent of Grade 4 (4= completely hard) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 4)/(number of occasions where Erection Hardness Scale was answered)
Time frame: Week 2, Week 4 and Week 6
Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of Grade 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Baseline | Grade 4 (Week 2) N=103 | 33.27 per-patient percentage | Standard Deviation 41.43 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of Grade 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Baseline | Grade 4 (Week 4) N=101 | 61.45 per-patient percentage | Standard Deviation 44.77 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of Grade 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Baseline | Grade 4 (Week 6) N=98 | 66.10 per-patient percentage | Standard Deviation 45.15 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of Grade 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Baseline | Grade 4 (Week 6 LOCF) N=103 | 64.84 per-patient percentage | Standard Deviation 45.7 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of Grade 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Baseline | Grade 4 (Week 6 Endpoint) N=101 | 65.13 per-patient percentage | Standard Deviation 45.56 |
Mean Per-Patient Percentage of Grade 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2
Mean change: mean change at each visit minus mean at Week 2. Percent of Grade 4 (4= completely hard) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 4)/(number of occasions where Erection Hardness Scale was answered)
Time frame: Week 4 and Week 6
Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of Grade 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2 | Grade 4 (Week 4) N=110 | 27.53 per-patient percentage | Standard Deviation 40.19 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of Grade 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2 | Grade 4 (Week 6) N=107 | 30.92 per-patient percentage | Standard Deviation 41.9 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of Grade 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2 | Grade 4 (Week 6 LOCF) N=112 | 30.43 per-patient percentage | Standard Deviation 41.88 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of Grade 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2 | Grade 4 (Week 6 Endpoint) N=110 | 30.98 per-patient percentage | Standard Deviation 42.06 |
Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 1 Based on Occasions With Sexual Stimulation- Change From Week 2
Mean change: mean change at each visit minus mean at Week 2. Percent of Yes responses to Question 1 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 1 \[Were you able to achieve at least some erection (some enlargement of the penis)?\] = Yes) / (number of occasions where Question 1 was answered Yes or No)
Time frame: Week 4 and Week 6
Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 1 Based on Occasions With Sexual Stimulation- Change From Week 2 | Question 1 (Week 4) N=111 | 1.37 per-patient percentage | Standard Deviation 14.85 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 1 Based on Occasions With Sexual Stimulation- Change From Week 2 | Question 1 (Week 6) N=108 | 3.12 per-patient percentage | Standard Deviation 14.26 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 1 Based on Occasions With Sexual Stimulation- Change From Week 2 | Question 1 (Week 6 LOCF) N=113 | 2.98 per-patient percentage | Standard Deviation 13.95 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 1 Based on Occasions With Sexual Stimulation- Change From Week 2 | Question 1 (Week 6 Endpoint) N=111 | 3.04 per-patient percentage | Standard Deviation 14.07 |
Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 1 on Occasions With Sexual Stimulation- Change From Baseline
Mean change: mean change at each visit minus mean at baseline. Percent of Yes responses to Question 1 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 1 \[Were you able to achieve at least some erection (some enlargement of the penis)?\] = Yes) / (number of occasions where Question 1 was answered Yes or No)
Time frame: Week 2, Week 4 and Week 6
Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 1 on Occasions With Sexual Stimulation- Change From Baseline | Question 1 (Week 2) N=110 | 8.84 per-patient percentage | Standard Deviation 28.7 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 1 on Occasions With Sexual Stimulation- Change From Baseline | Question 1 (Week 4) N=108 | 10.18 per-patient percentage | Standard Deviation 27.51 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 1 on Occasions With Sexual Stimulation- Change From Baseline | Question 1 (Week 6) N=105 | 12.29 per-patient percentage | Standard Deviation 28.88 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 1 on Occasions With Sexual Stimulation- Change From Baseline | Question 1 (Week 6 LOCF) N=110 | 11.96 per-patient percentage | Standard Deviation 28.33 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 1 on Occasions With Sexual Stimulation- Change From Baseline | Question 1 (Week 6 Endpoint) N=108 | 11.95 per-patient percentage | Standard Deviation 28.55 |
Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 2 on Occasions With Sexual Stimulation- Change From Baseline
Mean change: mean change at each visit minus mean at baseline. Percent of Yes responses to SEP Question 2 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 2 \[Were you able to insert your penis into your partner's vagina?\] = Yes) / (number of occasions where SEP Question 2 was answered Yes or No).
Time frame: Week 2, Week 4 and Week 6
Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 2 on Occasions With Sexual Stimulation- Change From Baseline | Question 2 (Week 2) N=102 | 15.37 per-patient percentage | Standard Deviation 30.51 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 2 on Occasions With Sexual Stimulation- Change From Baseline | Question 2 (Week 4) N=100 | 17.15 per-patient percentage | Standard Deviation 32.22 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 2 on Occasions With Sexual Stimulation- Change From Baseline | Question 2 (Week 6) N=97 | 18.22 per-patient percentage | Standard Deviation 32.44 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 2 on Occasions With Sexual Stimulation- Change From Baseline | Question 2 (Week 6 LOCF) N=102 | 17.33 per-patient percentage | Standard Deviation 31.87 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 2 on Occasions With Sexual Stimulation- Change From Baseline | Question 2 (Week 6 Endpoint) N=100 | 17.68 per-patient percentage | Standard Deviation 32.1 |
Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 2 on Occasions With Sexual Stimulation- Change From Week 2
Mean change: mean change at each visit minus mean at Week 2. Percent of Yes responses to SEP Question 2 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 2 \[Were you able to insert your penis into your partner's vagina?\] = Yes) / (number of occasions where SEP Question 2 was answered Yes or No).
Time frame: Week 4 and Week 6
Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 2 on Occasions With Sexual Stimulation- Change From Week 2 | Question 2 (Week 4) N=110 | 1.46 per-patient percentage | Standard Deviation 9.41 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 2 on Occasions With Sexual Stimulation- Change From Week 2 | Question 2 (Week 6) N=107 | 1.18 per-patient percentage | Standard Deviation 12.33 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 2 on Occasions With Sexual Stimulation- Change From Week 2 | Question 2 (Week 6 LOCF) N=112 | 1.13 per-patient percentage | Standard Deviation 12.05 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 2 on Occasions With Sexual Stimulation- Change From Week 2 | Question 2 (Week 6 Endpoint) N=110 | 1.15 per-patient percentage | Standard Deviation 12.16 |
Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 Based on Occasions With Sexual Stimulation- Change From Week 2
Mean change: mean change at each visit minus mean at Week 2. Percent of Yes responses to SEP Question 2 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 3 \[Did your erection last long enough for you to have successful intercourse?\] = Yes) / (number of occasions where SEP Question 3 was answered Yes or No)
Time frame: Week 4 and Week 6
Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 Based on Occasions With Sexual Stimulation- Change From Week 2 | Question 3 (Week 4) N=110 | 13.56 per-patient percentage | Standard Deviation 30.89 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 Based on Occasions With Sexual Stimulation- Change From Week 2 | Question 3 (Week 6) N=107 | 14.25 per-patient percentage | Standard Deviation 31.31 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 Based on Occasions With Sexual Stimulation- Change From Week 2 | Question 3 (Week 6 LOCF) N=112 | 14.51 per-patient percentage | Standard Deviation 31.77 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 Based on Occasions With Sexual Stimulation- Change From Week 2 | Question 3 (Week 6 Endpoint) N=110 | 14.77 per-patient percentage | Standard Deviation 32 |
Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 on Occasions With Sexual Stimulation- Change From Baseline
Mean change: mean change at each visit minus mean at baseline. Percent of Yes responses to SEP Question 2 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 3 \[Did your erection last long enough for you to have successful intercourse?\] = Yes) / (number of occasions where SEP Question 3 was answered Yes or No)
Time frame: Week 2, Week 4 and Week 6
Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 on Occasions With Sexual Stimulation- Change From Baseline | Question 3 (Week 2) N=102 | 56.96 per-patient percentage | Standard Deviation 38.93 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 on Occasions With Sexual Stimulation- Change From Baseline | Question 3 (Week 4) N=100 | 70.78 per-patient percentage | Standard Deviation 35.46 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 on Occasions With Sexual Stimulation- Change From Baseline | Question 3 (Week 6) N=97 | 71.23 per-patient percentage | Standard Deviation 35.79 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 on Occasions With Sexual Stimulation- Change From Baseline | Question 3 (Week 6 LOCF) N=102 | 72.15 per-patient percentage | Standard Deviation 35.41 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 on Occasions With Sexual Stimulation- Change From Baseline | Question 3 (Week 6 Endpoint) N=100 | 71.60 per-patient percentage | Standard Deviation 35.55 |
Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 (Q3) Based on Attempts With Sexual Stimulation- Change From Baseline
Mean change: mean change at each visit minus mean at baseline. Percent of Yes responses to SEP Q3 based on attempts with sexual stimulation (SS): 100\* (number of attempts with SS where SEP Q3 \[Did your erection last long enough for you to have successful intercourse?\] = Yes)/(number of attempts with SS where SEP Q3 was answered Yes or No)
Time frame: Week 2, Week 4, and Week 6
Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 (Q3) Based on Attempts With Sexual Stimulation- Change From Baseline | Week 2 (N=102) | 56.96 per-patient percentage | Standard Deviation 38.93 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 (Q3) Based on Attempts With Sexual Stimulation- Change From Baseline | Week 4 (N=100) | 70.78 per-patient percentage | Standard Deviation 35.46 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 (Q3) Based on Attempts With Sexual Stimulation- Change From Baseline | Week 6 (N=97) | 71.23 per-patient percentage | Standard Deviation 35.79 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 (Q3) Based on Attempts With Sexual Stimulation- Change From Baseline | Week 6 LOCF (N=102) | 72.15 per-patient percentage | Standard Deviation 35.41 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 (Q3) Based on Attempts With Sexual Stimulation- Change From Baseline | Week 6 Endpoint (N=100) | 71.60 per-patient percentage | Standard Deviation 35.55 |
Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 (Q3) Based on Attempts With Sexual Stimulation- Change From Week 2
Mean change: mean change at each visit minus mean at Week 2. Percent of Yes responses to SEP Q3 based on attempts with sexual stimulation (SS): 100\* (number of attempts with SS where SEP Q3 \[Did your erection last long enough for you to have successful intercourse?\] = Yes)/(number of attempts with SS where SEP Q3 was answered Yes or No)
Time frame: Week 4 and Week 6
Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 (Q3) Based on Attempts With Sexual Stimulation- Change From Week 2 | Week 4 (N=110) | 13.56 per-patient percentage | Standard Deviation 30.89 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 (Q3) Based on Attempts With Sexual Stimulation- Change From Week 2 | Week 6 (N=107) | 14.25 per-patient percentage | Standard Deviation 31.31 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 (Q3) Based on Attempts With Sexual Stimulation- Change From Week 2 | Week 6 LOCF (N=112) | 14.51 per-patient percentage | Standard Deviation 31.77 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 (Q3) Based on Attempts With Sexual Stimulation- Change From Week 2 | Week 6 Endpoint (N=110) | 14.77 per-patient percentage | Standard Deviation 32 |
Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 4 Based on Occasions With Sexual Stimulation- Change From Baseline
Mean change: mean change at each visit minus mean at baseline. Percent of Yes responses to SEP Question 4 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 4 \[Were you satisfied with the hardness of your erection?\] = Yes) / (number of occasions where SEP Question 4 was answered Yes or No).
Time frame: Week 2, Week 4 and Week 6
Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 4 Based on Occasions With Sexual Stimulation- Change From Baseline | Question 4 (Week 2) N=102 | 58.58 per-patient percentage | Standard Deviation 41.24 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 4 Based on Occasions With Sexual Stimulation- Change From Baseline | Question 4 (Week 4) N=100 | 76.29 per-patient percentage | Standard Deviation 37.21 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 4 Based on Occasions With Sexual Stimulation- Change From Baseline | Question 4(Week 6) N=97 | 77.69 per-patient percentage | Standard Deviation 37.26 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 4 Based on Occasions With Sexual Stimulation- Change From Baseline | Question 4 (Week 6 LOCF) N=102 | 78.79 per-patient percentage | Standard Deviation 36.65 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 4 Based on Occasions With Sexual Stimulation- Change From Baseline | Question 4 (Week 6 Endpoint) N=100 | 78.36 per-patient percentage | Standard Deviation 36.89 |
Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 4 Based on Occasions With Sexual Stimulation- Change From Week 2
Mean change: mean change at each visit minus mean at Week 2. Percent of Yes responses to SEP Question 4 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 4 \[Were you satisfied with the hardness of your erection?\] = Yes) / (number of occasions where SEP Question 4 was answered Yes or No).
Time frame: Week 4 and Week 6
Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 4 Based on Occasions With Sexual Stimulation- Change From Week 2 | Question 4 (Week 4) N=110 | 17.90 per-patient percentage | Standard Deviation 36.63 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 4 Based on Occasions With Sexual Stimulation- Change From Week 2 | Question 4 (Week 6) N=107 | 19.50 per-patient percentage | Standard Deviation 36.84 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 4 Based on Occasions With Sexual Stimulation- Change From Week 2 | Question 4 (Week 6 LOCF) N=112 | 19.52 per-patient percentage | Standard Deviation 36.99 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 4 Based on Occasions With Sexual Stimulation- Change From Week 2 | Question 4 (Week 6 Endpoint) N=110 | 19.88 per-patient percentage | Standard Deviation 37.23 |
Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 5 Based on Occasions With Sexual Stimulation- Change From Baseline
Mean change: mean change at each visit minus mean at baseline. Percent of Yes responses to SEP Question 5 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 5 \[Were you satisfied with this sexual encounter?\] = Yes) / (number of occasions where SEP Question 5 was answered Yes or No)
Time frame: Week 2, Week 4 and Week 6
Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 5 Based on Occasions With Sexual Stimulation- Change From Baseline | Question 5 (Week 2) N=101 | 57.34 per-patient percentage | Standard Deviation 42.6 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 5 Based on Occasions With Sexual Stimulation- Change From Baseline | Question 5 (Week 4) N=100 | 70.72 per-patient percentage | Standard Deviation 40.3 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 5 Based on Occasions With Sexual Stimulation- Change From Baseline | Question 5 (Week 6) N=97 | 70.63 per-patient percentage | Standard Deviation 40.78 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 5 Based on Occasions With Sexual Stimulation- Change From Baseline | Question 5 (Week 6 LOCF) N=102 | 72.07 per-patient percentage | Standard Deviation 40.27 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 5 Based on Occasions With Sexual Stimulation- Change From Baseline | Question 5 (Week 6 Endpoint) N=100 | 71.51 per-patient percentage | Standard Deviation 40.48 |
Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 5 Based on Occasions With Sexual Stimulation- Change From Week 2
Mean change: mean change at each visit minus mean at Week 2. Percent of Yes responses to SEP Question 5 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 5 \[Were you satisfied with this sexual encounter?\] = Yes) / (number of occasions where SEP Question 5 was answered Yes or No)
Time frame: Week 4 and Week 6
Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 5 Based on Occasions With Sexual Stimulation- Change From Week 2 | Question 5 (Week 4) N=109 | 13.10 per-patient percentage | Standard Deviation 29.11 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 5 Based on Occasions With Sexual Stimulation- Change From Week 2 | Question 5 (Week 6) N=106 | 14.11 per-patient percentage | Standard Deviation 32.53 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 5 Based on Occasions With Sexual Stimulation- Change From Week 2 | Question 5 (Week 6 LOCF) N=111 | 13.47 per-patient percentage | Standard Deviation 31.92 |
| Open Label Sildenafil Citrate | Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 5 Based on Occasions With Sexual Stimulation- Change From Week 2 | Question 5 (Week 6 Endpoint) N=109 | 13.72 per-patient percentage | Standard Deviation 32.16 |
Quality of Erection Questionnaire (QEQ): Total Score - Change From Baseline
QEQ is a self-administered scale used to assess erection hardness and overall quality of erections. The QEQ total score is defined as the sum of the scores from QEQ Questions 1-6. Score range: 1 to 5. Higher score indicates better outcome. Raw QEQ score ranges from 6-30 and is transformed onto a 0-100 scale.
Time frame: Week 2, Week 4, and Week 6
Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Open Label Sildenafil Citrate | Quality of Erection Questionnaire (QEQ): Total Score - Change From Baseline | Week 2 (N=113) | 32.71 score on scale | Standard Deviation 25.36 |
| Open Label Sildenafil Citrate | Quality of Erection Questionnaire (QEQ): Total Score - Change From Baseline | Week 4 (N=112) | 46.21 score on scale | Standard Deviation 26.27 |
| Open Label Sildenafil Citrate | Quality of Erection Questionnaire (QEQ): Total Score - Change From Baseline | Week 6 (N=110) | 45.53 score on scale | Standard Deviation 26.96 |
| Open Label Sildenafil Citrate | Quality of Erection Questionnaire (QEQ): Total Score - Change From Baseline | Week 6 LOCF (N=113) | 45.28 score on scale | Standard Deviation 27.01 |
| Open Label Sildenafil Citrate | Quality of Erection Questionnaire (QEQ): Total Score - Change From Baseline | Week 6 Endpoint (N=112) | 45.05 score on scale | Standard Deviation 27.02 |
Quality of Erection Questionnaire (QEQ): Total Score- Change From Week 2
QEQ is a self-administered scale used to assess erection hardness and overall quality of erections. The QEQ total score is defined as the sum of the scores from QEQ Questions 1-6. Score range: 1 to 5. Higher score indicates better outcome. Raw QEQ score ranges from 6-30 and is transformed onto a 0-100 scale.
Time frame: Week 4 and Week 6
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Open Label Sildenafil Citrate | Quality of Erection Questionnaire (QEQ): Total Score- Change From Week 2 | Week 6 (N=110) | 13.07 score on scale | Standard Deviation 24.25 |
| Open Label Sildenafil Citrate | Quality of Erection Questionnaire (QEQ): Total Score- Change From Week 2 | Week 4 (N=112) | 13.84 score on scale | Standard Deviation 21.1 |
| Open Label Sildenafil Citrate | Quality of Erection Questionnaire (QEQ): Total Score- Change From Week 2 | Week 6 LOCF (N=112) | 12.69 score on scale | Standard Deviation 24.26 |
| Open Label Sildenafil Citrate | Quality of Erection Questionnaire (QEQ): Total Score- Change From Week 2 | Week 6 Endpoint (N=112) | 12.69 score on scale | Standard Deviation 24.26 |
Sexual Experience Questionnaire (Sex-Q): Erection Domain - Change From Baseline
Sexual Experience Questionnaire (Sex-Q) is a self-administered questionnaire designed to assess functional, emotional, and social aspects of sexual experience. Sex-Q includes 15 questions. Sex-Q Erection domain: sum of scores for Questions 1, 2, 3, 4, 5 and 6 from the Sex-Q. Score range: 1 to 5; total 6 to 30. Higher score indicates better outcome.
Time frame: Week 2, Week 4 and Week 6
Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Open Label Sildenafil Citrate | Sexual Experience Questionnaire (Sex-Q): Erection Domain - Change From Baseline | Week 2 (N=113) | 5.41 score on scale | Standard Deviation 4.4 |
| Open Label Sildenafil Citrate | Sexual Experience Questionnaire (Sex-Q): Erection Domain - Change From Baseline | Week 4 (N=112) | 8.85 score on scale | Standard Deviation 4.96 |
| Open Label Sildenafil Citrate | Sexual Experience Questionnaire (Sex-Q): Erection Domain - Change From Baseline | Week 6 (N=110) | 9.21 score on scale | Standard Deviation 5.19 |
| Open Label Sildenafil Citrate | Sexual Experience Questionnaire (Sex-Q): Erection Domain - Change From Baseline | Week 6 LOCF (N=113) | 9.28 score on scale | Standard Deviation 5.14 |
| Open Label Sildenafil Citrate | Sexual Experience Questionnaire (Sex-Q): Erection Domain - Change From Baseline | Week 6 Endpoint (N=112) | 9.25 score on scale | Standard Deviation 5.15 |
Sexual Experience Questionnaire (Sex-Q): Erection Domain- Change From Week 2
Sexual Experience Questionnaire (Sex-Q) is a self-administered questionnaire designed to assess functional, emotional, and social aspects of sexual experience. Sex-Q includes 15 questions. Sex-Q Erection domain: sum of scores for Questions 1, 2, 3, 4, 5 and 6 from the Sex-Q. Score range: 1 to 5; total 6 to 30. Higher score indicates better outcome.
Time frame: Week 4 and Week 6
Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Open Label Sildenafil Citrate | Sexual Experience Questionnaire (Sex-Q): Erection Domain- Change From Week 2 | Week 4 (N=112) | 3.51 score on scale | Standard Deviation 3.89 |
| Open Label Sildenafil Citrate | Sexual Experience Questionnaire (Sex-Q): Erection Domain- Change From Week 2 | Week 6 (N=110) | 3.91 score on scale | Standard Deviation 4.41 |
| Open Label Sildenafil Citrate | Sexual Experience Questionnaire (Sex-Q): Erection Domain- Change From Week 2 | Week 6 LOCF (N=112) | 3.91 score on scale | Standard Deviation 4.38 |
| Open Label Sildenafil Citrate | Sexual Experience Questionnaire (Sex-Q): Erection Domain- Change From Week 2 | Week 6 Endpoint (N=112) | 3.91 score on scale | Standard Deviation 4.38 |
Sexual Experience Questionnaire (Sex-Q): Relationship Domain - Change From Baseline
Sexual Experience Questionnaire (Sex-Q) is a self-administered questionnaire designed to assess functional, emotional, and social aspects of sexual experience. Sex-Q includes 15 questions. Sex-Q Relationship domain was sum of scores for Questions 7, 8 and 9 from the Sex-Q. Score range: 1 to 5; total 3 to 15. Higher score indicates better outcome.
Time frame: Week 2, Week 4, and Week 6
Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Open Label Sildenafil Citrate | Sexual Experience Questionnaire (Sex-Q): Relationship Domain - Change From Baseline | Week 2 (N=112) | 2.79 score on scale | Standard Deviation 2.44 |
| Open Label Sildenafil Citrate | Sexual Experience Questionnaire (Sex-Q): Relationship Domain - Change From Baseline | Week 4 (N=111) | 4.23 score on scale | Standard Deviation 2.56 |
| Open Label Sildenafil Citrate | Sexual Experience Questionnaire (Sex-Q): Relationship Domain - Change From Baseline | Week 6 (N=108) | 4.74 score on scale | Standard Deviation 2.84 |
| Open Label Sildenafil Citrate | Sexual Experience Questionnaire (Sex-Q): Relationship Domain - Change From Baseline | Week 6 LOCF (N=111) | 4.78 score on scale | Standard Deviation 2.81 |
| Open Label Sildenafil Citrate | Sexual Experience Questionnaire (Sex-Q): Relationship Domain - Change From Baseline | Week 6 Endpoint (N=110) | 4.76 score on scale | Standard Deviation 2.82 |
Sexual Experience Questionnaire (Sex-Q): Relationship Domain - Change From Week 2
Sexual Experience Questionnaire (Sex-Q) is a self-administered questionnaire designed to assess functional, emotional, and social aspects of sexual experience. Sex-Q includes 15 questions. Sex-Q Relationship domain was sum of scores for Questions 7, 8 and 9 from the Sex-Q. Score range: 1 to 5; total 3 to 15. Higher score indicates better outcome.
Time frame: Week 4 and Week 6
Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Open Label Sildenafil Citrate | Sexual Experience Questionnaire (Sex-Q): Relationship Domain - Change From Week 2 | Week 4 (N=112) | 1.49 score on scale | Standard Deviation 1.91 |
| Open Label Sildenafil Citrate | Sexual Experience Questionnaire (Sex-Q): Relationship Domain - Change From Week 2 | Week 6 (N=109) | 1.96 score on scale | Standard Deviation 2.08 |
| Open Label Sildenafil Citrate | Sexual Experience Questionnaire (Sex-Q): Relationship Domain - Change From Week 2 | Week 6 LOCF (N=111) | 1.98 score on scale | Standard Deviation 2.07 |
| Open Label Sildenafil Citrate | Sexual Experience Questionnaire (Sex-Q): Relationship Domain - Change From Week 2 | Week 6 Endpoint (N=111) | 1.98 score on scale | Standard Deviation 2.07 |
Sexual Experience Questionnaire (Sex-Q): Satisfaction Domain - Change From Baseline
Sexual Experience Questionnaire (Sex-Q) is a self-administered questionnaire designed to assess functional, emotional, and social aspects of sexual experience. Sex-Q includes 15 questions (q). Sex-Q Satisfaction domain:sum of scores for q 10, 11, 12, 13, 14 and 15 from Sex-Q. Score range:1 to 5; total 6 to 30. Higher score indicates better outcome
Time frame: Week 2, Week 4, and Week 6
Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Open Label Sildenafil Citrate | Sexual Experience Questionnaire (Sex-Q): Satisfaction Domain - Change From Baseline | Week 2 (N=113) | 6.68 score on scale | Standard Deviation 4.86 |
| Open Label Sildenafil Citrate | Sexual Experience Questionnaire (Sex-Q): Satisfaction Domain - Change From Baseline | Week 4 (N=112) | 9.94 score on scale | Standard Deviation 5.21 |
| Open Label Sildenafil Citrate | Sexual Experience Questionnaire (Sex-Q): Satisfaction Domain - Change From Baseline | Week 6 (N=108) | 10.59 score on scale | Standard Deviation 5.08 |
| Open Label Sildenafil Citrate | Sexual Experience Questionnaire (Sex-Q): Satisfaction Domain - Change From Baseline | Week 6 LOCF (N=111) | 10.63 score on scale | Standard Deviation 5.03 |
| Open Label Sildenafil Citrate | Sexual Experience Questionnaire (Sex-Q): Satisfaction Domain - Change From Baseline | Week 6 Endpoint (N=110) | 10.64 score on scale | Standard Deviation 5.06 |
Sexual Experience Questionnaire (Sex-Q): Satisfaction Domain - Change From Week 2
Sexual Experience Questionnaire (Sex-Q) is a self-administered questionnaire designed to assess functional, emotional, and social aspects of sexual experience. Sex-Q includes 15 questions (q). Sex-Q Satisfaction domain:sum of scores for q 10, 11, 12, 13, 14 and 15 from Sex-Q. Score range:1 to 5; total 6 to 30. Higher score indicates better outcome
Time frame: Week 4 and Week 6
Population: MITT population consists of subjects in the safety population who provided at least 1 post baseline efficacy assessment. The Week 6 Last Observation Carried Forward (LOCF) value is the last post-baseline value, ie, the last assessment among those collected at visits after Visit 1. Week 6 Endpoint = last observation recorded after Week 2
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Open Label Sildenafil Citrate | Sexual Experience Questionnaire (Sex-Q): Satisfaction Domain - Change From Week 2 | Week 4 (N=112) | 3.29 score on scale | Standard Deviation 4.1 |
| Open Label Sildenafil Citrate | Sexual Experience Questionnaire (Sex-Q): Satisfaction Domain - Change From Week 2 | Week 6 (N=108) | 4.03 score on scale | Standard Deviation 5.09 |
| Open Label Sildenafil Citrate | Sexual Experience Questionnaire (Sex-Q): Satisfaction Domain - Change From Week 2 | Week 6 LOCF (N=110) | 4.01 score on scale | Standard Deviation 5.04 |
| Open Label Sildenafil Citrate | Sexual Experience Questionnaire (Sex-Q): Satisfaction Domain - Change From Week 2 | Week 6 Endpoint (N=110) | 4.01 score on scale | Standard Deviation 5.04 |